Longer-term study reports cardiovascular risks posed by Vioxx

10/13/2008 | Washington Post, The · Google

A worldwide study of Merck & Co.'s Vioxx found that patients had a 79% higher risk of stroke, heart attack or death a year after they stopped using the pain drug compared with those who took placebo. Study researchers and other experts said the finding indicates that long-term use of nonsteroidal anti-inflammatory drugs also can boost such risks to some extent. Vioxx, also known as rofecoxib, was withdrawn from the global market in 2004.

View Full Article in:

Washington Post, The · Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA